Purpose: We sought to determine the rate of upgrading to Gleason score 4 þ 3 or greater using targeted biopsy for diagnosis and monitoring in men undergoing active surveillance of prostate cancer. Materials and Methods: Study subjects comprised all 259 men, including 196 with Gleason score 3 þ 3 and 63 with Gleason score 3 þ 4, who were diagnosed by magnetic resonance imaging/ultrasound fusion guided biopsy from 2009 to 2015 and underwent subsequent fusion biopsy for as long as 4 years of active surveillance. The primary end point was the discovery of Gleason score 4 þ 3 or greater prostate cancer. Followup biopsies included targeting of positive sites, which were tracked in an ArtemisÔ device. Kaplan-Meier curves were generated to determine upgrading rates, stratified by initial Gleason score and prostate specific antigen density. Results: Based on a Cox proportional hazard model, men with Gleason score 3 þ 4 were 4.65 times more likely to have upgrading than men with an initial Gleason score of 3 þ 3 at 3 years (p <0.01). By the third surveillance year 63% of men with Gleason score 3 þ 4 had been upgraded compared with 18.0% who started with Gleason score 3 þ 3 (p <0.01). Of all 33 upgrades 32 (97%) occurred at a magnetic resonance imaging visible or a tracked site of tumor, rather than at a previously negative systematic site. Independent predictors of upgrading were Gleason score 3 þ 4, prostate specific antigen density 0.15 ng/ml/cm 3 or greater and a grade 5 lesion on magnetic resonance imaging. The incidence rate ratio of upgrading (Gleason score 3 þ 4 vs 3 þ 3) was 4.25 per year of patient followup (p <0.01). Conclusions: During active surveillance of prostate cancer, targeting of tracked tumor foci by magnetic resonance imaging/ultrasound fusion biopsy allows for Accepted for publication September 7, 2016. No direct or indirect commercial incentive associated with publishing this article. The corresponding author certifies that, when applicable, a statement(s) has been included in the manuscript documenting institutional review board, ethics committee or ethical review board study approval; principles of Helsinki Declaration were followed in lieu of formal ethics committee approval; institutional animal care and use committee approval; all human subjects provided written informed consent with guarantees of confidentiality; IRB approved protocol number; animal approved project number.
heightened detection of Gleason score 4 þ 3 or greater cancers. Baseline variables directly related to important upgrading that warrant increased vigilance include Gleason score 3 þ 4, prostate specific antigen density 0.15 ng/ml/cm 3 or greater and grade 5 lesions on magnetic resonance imaging.
Key Words: prostatic neoplasms, watchful waiting, magnetic resonance imaging, ultrasonography, image-guided biopsy BIOPSY criteria for AS vary from one program to another. 1 In the original Epstein criteria AS was offered only for men with small GS 3 þ 3 CaP. 2 However, in various programs the criteria now include men with more extensive GS 3 þ 3 lesions and even some with GS 3 þ 4. 1, 3, 4 In the latter men (GS 3 þ 4 and intermediate risk) pathological upgrading has been observed more often than in men with low risk lesions (GS 3 þ 3). 1 In virtually all AS programs GS 4 þ 3 or greater would be considered exclusionary and would ordinarily trigger active intervention if detected during the surveillance period. Biopsy GS is the most important factor for both initial selection and continued eligibility for AS. 4 However, in most AS programs biopsy has been performed using conventional US guidance. In 2009 an AS registry at UCLA was initiated using MRI guided biopsy 5, 6 in all participants at baseline and during followup. MRI guided biopsy more accurately characterizes whole organ pathology than conventional US guided biopsy. 7e9 In previous studies we and others have found that MRI guided biopsy including target and template samples 10 helps detect csCaP in men being screened for AS. 11, 12 In the current study we sought to determine continued AS eligibility for men entering the registry with low risk (GS 3 þ 3) vs intermediate risk (GS 3 þ 4) lesions. MRI guidance was used for all biopsies, and an appearance of GS 4 þ 3 or greater served as a clear point of AS termination. The main finding, which was that the subsequent detection of potentially aggressive disease is much more common in men who start AS with a Gleason 4 component than in men without it, may have important implications for men with such lesions who are considering AS. Figure 1 shows the study design. Subjects were all men with clinical stage T1c and an initial diagnosis of GS 3 þ 3 or 3 þ 4 CaP (ie low or intermediate risk by D'Amico histological criteria 13 ) made by fusion biopsy who entered AS at UCLA from 2009 through 2015 and underwent 1 or more followup fusion biopsies within 1 to 4 years. Serum PSA testing and digital rectal examination were done every 6 months and a fusion biopsy was performed within 1 year after the confirmatory biopsy. Thereafter, fusion biopsy with repeat mpMRI was performed at 2-year intervals. All patients who had not been seen for biopsy in the previous 15 months (those possibly lost to followup) were contacted by telephone to verify that definitive treatment had not occurred outside the study.
METHODS

Study Cohort
Pathological upgrading, which was the primary outcome, was defined as the appearance of Gleason primary pattern 4 or greater, or secondary pattern 5 on any followup surveillance biopsy. All data collection was performed in a UCLA institutional review board approved registry.
Magnetic Resonance Imaging/Ultrasound Guided Targeted Biopsy
The fusion biopsy method, which has been previously described, was unchanged throughout the study period.
5, 14 Briefly, within 2 months of biopsy patients underwent 3-Tesla mpMRI using a body coil. MRI was interpreted under the direction of a dedicated uroradiologist (DJM), and ROIs were graded according to UCLA and PI-RADSÔ criteria.
5,15 MRI grading was based on the UCLA scoring system, which pre-dates PI-RADS-1 and, after PI-RADS-2 was established, by both systems using highest grade found. At biopsy the images were registered and fused with real-time transrectal US using a NoblusÔ device to generate a 3-dimensional image of the prostate with delineated ROIs (targets).
Template and target samples were taken by a single urologist (LSM) at UCLA Clark Urology Center using the Artemis device with the patient under local anesthesia.
5, 14 The intraprostatic location of biopsy cores with CaP were tracked and specifically resampled on followup biopsies as described previously. 16 A dedicated uropathologist interpreted all biopsy cores (JH).
Statistical Analysis
Kaplan-Meier curves were generated to determine time to the appearance of GS 4 þ 3 or greater in years from time zero, defined as the time of initial fusion biopsy showing cancer. Men who withdrew from AS, were lost to followup or who died while on AS were censored at the date of the last surveillance visit. Followup is reported in years between time zero and the time to patient censoring or reclassification.
The log-rank test was used to determine whether the probability of upgrading between the GS 3 þ 3 and 3 þ 4 groups was statistically significant. Cox proportional hazard analysis was used for all other time dependent covariates to identify independent predictors of histological reclassification. Statistical significance was considered at p <0.05 for all analyses. Statistical analyses were performed by one of us (FJD) using StataÒ, version 13.1.
RESULTS
Of 1,388 men who underwent MRI/US fusion biopsy during the study period 340 were diagnosed with GS 3 þ 3 and 268 were diagnosed with GS 3 þ 4 CaP. In the GS 3 þ 3 arm 196 men (57.6%) entered AS, 48 (14.1%) were definitively treated and 14 (4.1%) were lost to followup. In the GS 3 þ 4 arm 63 men (23.5%) entered AS, 173 (67.1%) were treated and 3 (1.2%) were lost to followup. For individual men guidelines for choosing active treatment or entering AS was not structured, except Gleason primary pattern 4 or greater, or secondary pattern 5 was exclusionary for AS. Table 1 lists baseline characteristics of men who entered AS.
Overall, pathological upgrading to GS 4 þ 3 or greater was found in 17 of 196 men (8.7%) who initially presented with GS 3 þ 3 and in 16 of 63 (25.4%) who initially presented with GS 3 þ 4 (p <0.01). The annual reclassification rate was 5.5% (17 upgrades over 305.2 years of patient followup) for GS 3 þ 3 and 23.4% (16 upgrades over 68.2 years of patient followup) for GS 3 þ 4 (p <0.01). The incidence rate ratio of upgrading for GS 3 þ 4 vs GS 3 þ 3 was 4.25 per year of patient followup (p <0.01). Table 2 shows the distribution of tumor locations (within a ROI vs template) at baseline and at the time of upgrading. Overall, upgrades in 16 of 17 patients (94%) with GS 3 þ 3 and all upgrades in the 16 with GS 3 þ 4 occurred within an MRI defined ROI or at a prior positive tracked site. No tracked site upgrades were found within the same quadrant as the MRI visible target. Figure 2 shows an example of MRI guided biopsy and tracking of positive sites. Table 3 lists univariate analysis results of the baseline characteristics of the 2 groups with upgrading as the primary outcome. Based on a Cox proportional hazards model, men with GS 3 þ 4 were 4.65 times more likely to experience upgrading than men with GS 3 þ 3 (HR 2.4, p <0.01). Other biopsy characteristics, such as maximum cancer core length 4 mm or greater, maximum percent of tumor involvement 60% or greater and number of positive biopsy cores greater than 3, were not significantly associated with an increased reclassification risk. Total serum PSA 10 ng/ml or greater was associated with an approximately twofold increase in reclassification risk (p not significant). Men with percent free PSA 10% or less and PSAD 0.15 ng/ml/cm 3 or greater (defined as serum PSA in ng/ml divided by prostate volume in cc determined on mpMRI) were 3.75 and 3.43 times (each p <0.01) more likely to undergo pathological upgrading in AS compared to men with more favorable values.
Baseline mpMRI did not predict the risk of reclassification except in the 12 men with a grade 5 lesion, in whom the risk of future reclassification was great (HR 5.16, p <0.01). All men with grade 5 ROIs were reclassified within 2.5 years. Of the 7 patients with GS 3 þ 3 disease and a grade 5 ROI only 1 remained stable on AS beyond 2 years. All 5 patients with GS 3 þ 4 and a baseline grade 5 ROI had been upgraded by 1 year. The annual rate of upgrading for all other MRI grades combined (0 to 4) was approximately 8% without evidence of risk stratification by grade. Kaplan-Meier estimates of the probability of upgrading over 3 years was determined ( fig. 3 ). Of patients with GS 3 þ 4 63.0% were reclassified by the third surveillance year compared to 18.0% of those with GS 3 þ 3 (log-rank test p <0.01, fig. 3, A) . The annual HR was 5.23, 4.12 and 4.65 by the first, second and third surveillance years, respectively (p <0.01).
The combination of GS and baseline PSAD was further analyzed (fig. 3, B) . Cases with the least favorable clinical histological profile (GS 3 þ 4 and PSAD 0.15 or greater) had the greatest incidence of upgrading, and 33% had upgraded to GS 4 þ 3 or greater by 1.3 years. Among men with GS 3 þ 4 CaP and PSAD less than 0.15 ng/ml/cm 3 , 34% had upgraded by the third year. In the group at lowest risk, that is men with GS 3 þ 3 and PSAD less than 0.15 ng/ml/cm 3 , only 15% had upgraded by the third surveillance year. Men in the 2 groups had a similar number of total biopsy cores (mean 14.3 vs 14.1, p not significant) and targeted cores (mean 4.3 vs 4.4, p ¼ not significant) taken at each session. Table 4 lists survival functions and 95% CIs.
Stepwise multivariate analysis of the strongest predictors of reclassification (table 5) confirmed that GS 3 þ 4 on initial fusion biopsy, a grade 5 ROI on mpMRI and PSAD 0.15 ng/ml/cm 3 or greater were significant independent predictors of future reclassification risk (p <0.005). Total PSA level and percent free PSA did not have a statistically significant association with reclassification risk on multivariate analysis.
DISCUSSION
The current study of AS differs from others in that all men were initially diagnosed by MRI/US fusion biopsy and all were followed with serial fusion biopsies. The central findings are that 1) men with GS 3 þ 4 who entered AS had more than 4 times the likelihood of later showing potentially aggressive disease (GS 4 þ 3 or greater) than men who entered AS with GS 3 þ 3, and 2) PSAD and a grade 5 ROI on mpMRI were important predictors of subsequent upgrading. Of 24 men who entered AS with the combination of GS 3 þ 4 and PSAD 0.15 ng/ml/cm 3 or greater, 8 were found upon subsequent fusion biopsy to have upgraded within 1.3 years of followup. In addition, all 12 men with a grade 5 ROI on mpMRI were likewise upgraded within the study period regardless of initial GS.
The discovery of primary GS 4 or greater, or secondary GS 5 was used as the main outcome of interest because such lesions carry substantial metastatic potential.
17e19 Thus, crossing the threshold from primary pattern 3, when immediate risk appears to be limited, 20 to primary 4 or secondary pattern 5, when risk is appreciable, was used as a discrete point for the discontinuance of AS. The increased sensitivity of MRI guided biopsy for detecting csCaP, which has been widely reported for other situations, 7e9,21 also appears valuable when the new modality is used for men in AS. Of the 33 upgrades 32 (97%) were detected by targeted biopsy of a MRI defined ROI (21 upgrades) or tracked sites (11 upgrades). Both targeted and template biopsies were obtained in all patients at baseline because of the possibility of csCaP outside a MRI visible target. 10 In large, well established AS programs the rate of patient discontinuance, which includes a variety of reasons in addition to upgrading, has ranged from 24% to 40% during 5 years of followup. 22e24 In these studies most men entered with GS 3 þ 3. However, in men entering with elements of Gleason pattern 4 in programs at Sunnybrook Health Sciences Centre and Royal Marsden Hospital, and who were diagnosed by conventional biopsy, the risk of progressive disease was found to be increased. 23, 25 In fact, a recent report documents the possibility of metastatic disease in men who enter AS with secondary Gleason pattern 4. 26 The current data confirm and quantify the GS related risk using MRI guided biopsies on KaplanMeier curves. Upgrading to unfavorable pathology findings over 3 years was found in 63% of men who fig. 3, B) , an important variable that was first identified more than 20 years ago by Epstein et al.
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According to the modified Epstein criteria, men with GS 3 þ 3 lesions are acceptable for AS if no more than 3 positive cores are present and no core contains more than 60% tumor involvement. 27 However, in the current study many men in whom pathology findings exceeded those strict criteria remained stable for up to 4 years of surveillance. Only 1 of the 11 men with initial GS 3 þ 3 and greater than 60% core involvement progressed to GS 4 þ 3 or greater. Through increased detection and exclusion of high grade cancer at baseline, the new biopsy method may help explain the relatively limited amount of upgrading from GS 3 þ 3 seen in this study during AS followup.
Limitations of the current study include the retrospective nature of the data analysis, although data were collected prospectively in an institutional review board approved registry. Not all eligible patients were followed for the entirety of the study period because of various interventions. Two men who were lost to followup during the course of the study were censored at the time of their last surveillance biopsy. The length of GS 4 components in mm on biopsy cores was not recorded initially and could be a factor in outcomes. Followup was relatively short but outcomes were clear by the end of the third year and longer followup would not have materially influenced group differences near term. Numbers were relatively small but the number of men (63) who entered AS with GS 3 þ 4 compared favorably to that in other available reports. Costeffectiveness has not yet been established.
Biopsies and MRI interpretations were performed by individuals with considerable experience, perhaps limiting how much these data can be generalized to less experienced personnel. However, the difference in outcomes between the 2 matched groups is dramatic and unlikely to disappear in a study lacking the above limitations.
The data presented should not be used to establish criteria for entry into AS or set rules of termination. However, the current findings suggest 1) the importance of continued vigilance during followup, especially of GS 3 þ 4 lesions, and 2) the advantage of MRI guided biopsy in detecting potentially aggressive disease. The AS protocol outlined includes initial diagnostic biopsy, confirmatory biopsy within a year, a followup biopsy a year later and then a biopsy every 2 years thereafter, all using MRI guidance and biopsy site tracking. With continued evolution of AS, such protocols will likely change in the future but the utility of MRI guided biopsy in any management strategy appears to offer a substantial advantage over blind biopsy.
CONCLUSIONS
Men entering AS with GS 3 þ 4 lesions have a much greater chance of subsequent upgrading to GS 4 þ 3 or greater than men entering with GS 3 þ 3 (63% vs 18% at 3 years). Adding PSAD helps stratify the chance of upgrading. A third of all 24 patients with GS 3 þ 4 and PSAD 0.15 ng/ml/cm 3 or greater were upgraded by 1.3 years of surveillance. MRI guided fusion biopsy, especially the tracking utility to resample prior positive sites, appears to provide added value in the detection of potentially aggressive cancer in men undergoing AS.
